Drug Trial Radar · NCT01606345
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Apr 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
Jul 2012
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Endo USA Inc., a Keenova Therapeutics Company
- First posted
- May 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn more about how well the drug valrubicin (VALSTAR®) works to help treat the patient's cancer when administered through a nephrostomy tube inserted through their back into their kidney. The study is also being done to determine how safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in which the drug is eliminated from the human body (Pharmacokinetics or PK).
Conditions
- Urothelial Carcinoma
Interventions
ValrubicinDrug
Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.